3 May 2018

$5M Capital Raising Completion

Antisense Therapeutics Limited ("ANP" or "the Company") advises that it has completed the 1 for 1 non-renounceable entitlement offer ("Entitlement Offer") announced on 6 April 2018.

The Entitlement Offer enabled existing shareholders the opportunity to participate in the capital raising on the same terms as the Company's institutional placement to Australian Ethical Investment as announced on 3 April 2018 ("Placement").

Under the Entitlement Offer of up to 185,793,319 shares, the Company received entitlement acceptances from shareholders for a total of 81,089,870 shares, raising $1.95 million and resulting in a shortfall of 104,703,449 shares or $2.5 million.

As previously advised XEC Partners, Lead Manager for the Placement and the Entitlement Offer had binding priority commitments of $3.5 million from new investors and existing shareholders, including Australian Ethical Investment, Platinum Asset Management, CVC Limited, Mr Leon Serry AM and clients of XEC Partners and sufficient to cover the shortfall under the Entitlement Offer.

The settlement of shortfall under the Entitlement Offer, allotment and commencement of trading of new shares and shortfall shares is scheduled to take place as per the Entitlement Offer timetable.

Pursuant to the capital raising, the Company has successfully raised the target amount of $5.0 million. Funds raised will be utilised to complete and report on the ATL1102 Phase II clinical trial in Duchenne Muscular Dystrophy patients, and to initiate the ATL1103 Early Access Program for Acromegaly patients.

Contact Information:
Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (3) 9827 8999

About Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical company, developing and commercialising antisense pharmaceuticals for large unmet markets. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ:IONS), world leaders in antisense drug development and commercialisation. ATL1102 (injection) has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). ATL1103 drug designed to block GHr production successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.